NCT07039331Recruiting
Short-term Fasting Compared to Free Diet on Ovarian Cancer Patients
The Effects of Short-term Fasting Compared to Free Diet on Ovarian Cancer Patients: A 2-Arms Pilot Randomized Study
Source: ClinicalTrials.gov · Last updated 1 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The primary endpoint of the study is the reduction of insulin levels between the two groups. Using the Student's t-test, while maintaining the study power at 95% and the significance level at 5%, a sample of 27+27 patients will allow the identification of differences in terms of Cohen's d equal to 1.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 54 (estimated)
- First submitted
- 5 Mar 2025
- Start date
- 7 Dec 2021
- Primary completion date
- 1 Apr 2026
- Lead sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Diseases
- Ovarian cancer
- NCT number
- NCT07039331
What you commit to
- Study type: Interventional
- Planned participants: 54
- From 7 Dec 2021 to the primary completion date, 1 Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- No other invasive malignancy within the past 5 years;
- Diabetes mellitus;
- myocardial infarction, stroke or pulmonary embolism within the last 3 months;
- Electrocardiogram (ECG) demonstrating clinically significant arrhythmias that are not adequately medically managed (Note: subjects with chronic atrial arrhythmia, ie, atrial fibrillation or paroxysmal supraventricular tachycardia \[SVT\], are eligible)
- Active serious systemic disease, including active bacterial or fungal infection
- Active viral hepatitis or active human immunodeficiency virus (HIV) infection. Asymptomatic positive serology is not exclusionary
- heart failure ≥III NYHA
- Significant food allergies which would make the subject unable to consume the food provided;
- History of or manifest eating disorder;
Other
- Pregnancy or lactating;
- Impaired physical mobility.
Who the study is looking for
- Female, aged 18 years or older;
- Histologically or cytologically documented invasive epithelial OC, primary peritoneal carcinoma, or fallopian tube cancer not suitable for primary cytoreduction, but requiring NACT;
- FIGO Stage III-IV;
- No previous treatment for EOC;
- BMI (Body Mass Index) ≥19 kg/m2;
- ECOG (Eastern Cooperative Oncology Group) performance status 0-2;
- Anticipated life expectancy of \>3 months;
- Adequate organ functions:
- Hematopoietic; Absolute neutrophil count ≥ 1,500/mm\^3; Platelet count ≥ 100,000/mm\^3; Hemoglobin ≥ 9 g/Dl
- Hepatic; AST and ALT ≤ 2.5 times upper limit of normal (ULN)\* ; Alkaline Phosphatase ≤ 2.5 times ULN\* ; Bilirubin ≤ 1.5 times ULN NOTE: \* ≤ 3 times ULN if liver metastases are present
- Renal: Creatinine Clearance ≥ 45 ml/min or Serum Creatinine ≤1.5 x ULN
- Serum Albumin \>2.5 g/dl;
- Patients must be accessible for treatment and follow-up;
- Written informed consent according to the local Ethics Committee requirements
- Patients with child-bearing potential using (or willing to use) effective contraception during treatment and 3 months ahead unless they are postmenopausal (at least 12 months consecutive amenorrhea, in the appropriate age group and without other known or suspected cause), or have been sterilized surgically
- Evidence of not pregnancy status as documented by a negative beta-human chorionic gonadotropin (ß-hCG) test
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| DH Tumori Femminili Coordinator of this site? Confirm its status | Roma | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.